Authors

Latest:

Dr. Hughes on Switching From Imatinib to Nilotinib in CML

Timothy P. Hughes, MD, MBBS, explains the two-year follow-up results of the ENESTcmr trial analyzing the switch to nilotinib after at least 2 years on imatinib in patients with chronic phase chronic myeloid leukemia.

Timothy S. Pardee, MD

Latest:

Dr. Pardee on CPI-613 for Patients With R/R AML

Timothy S. Pardee, MD, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).

Timothy Saettele, MD

Latest:

Dr. Saettele on the Benefits of Using Bronchoscopies in NSCLC

Timothy Saettele, MD, interventional pulmonologist at Saint Luke’s Hospital, discusses the benefits of using bronchoscopies in patients with non–small cell lung cancer (NSCLC).

Tina Cascone, MD, PhD

Latest:

Practice Pearls for Community Oncologists Treating Early-Stage NSCLC

A panel of experts share unmet needs and clinical practice pearls for community oncologists regarding the treatment of patients with early-stage NSCLC.

Tiziano Barbui, MD

Latest:

Dr. Barbui on Hematocrit Levels in Polycythemia Vera

Tiziano Barbui, MD, USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy, on hematocrit (HCT) levels in patients with polycythemia vera (PV).

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD

Latest:

Dr. Eyre on the Design of the BRUIN-MCL-321 Trial in MCL

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial in mantle cell lymphoma.

Toby Eyre, MCBhB, MRCP

Latest:

Dr. Eyre on Resistance to BTK Inhibition in MCL

Toby Eyre, MCBhB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses resistance to BTK inhibition in mantle cell lymphoma (MCL).

Todd A. Yezefski, MD

Latest:

Dr. Yezefski on Differences in CRC Care Costs Between the US and Canada

Todd A. Yezefski, MD, senior fellow, Fred Hutchinson Cancer Research Center, University of Washington, discusses the differences between colorectal cancer care costs in the Unites States and Canada.

Todd Bauer, MD

Latest:

Dr. Bauer on Evolution of Phase I Trials

Todd Bauer, MD, associate director, Drug Development, principal investigator, Sarah Cannon Research Institute, discusses how phase I clinical trial programs are evolving and becoming more beneficial for patients with cancer.

Todd Cooperman, PharmD, RPh

Latest:

Therapy Class Review: Blood Modifiers

In reviewing the therapeutic category of blood modifiers, there are 3 areas of focus

Todd E. Schlesinger, MD, FAAD, FASMS, Dermatology & Laser Center of Charleston

Todd Kunkler

Latest:

Carriers of Mutation Responsible for Multiple Endocrine Neoplasia Can Face Difficult Choices

Results of a multi-generational case study strengthen the case for genetic screening in cases of hereditary thyroid cancer.

Tom Henricks

Latest:

Henricks Applies NASA Concepts to Medicine at Prostate Congress

Former NASA astronaut Tom Henricks will show how team dynamics and organizational culture affect outcomes using dramatic real-life video shot inside of a NASA space shuttle cockpit during launch and landing, as well as scenes of working in space, during a keynote address at the 8th Annual Interdisciplinary Prostate Cancer Congress (IPCC): and Other Genitourinary Malignancies.

Tomasz Beer, MD

Latest:

Future of Multi-Cancer Early Detection: A Recap and Horizon

Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.

Tomi Jun, MD

Latest:

Dr. Jun on the Results of a Study Investigating Cyptogenic Hepatocellular Carcinoma

Tomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).

Tomoko Kurita, MD

Latest:

Clinical Utility of Emerging Molecular Diagnostics in Breast Cancer

The past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.

Tomoko Tagawa, MD

Latest:

Breast Cancer Chemoprevention: Targeting the Estrogen Receptor

New strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.

Toni Choueiri, MD

Latest:

Dr Choueiri on the Significance of Targeting HIF-2α With NKT2152 in ccRCC

Toni K. Choueiri, MD, discusses the significance of targeting HIF-2α using NKT2152 in previously treated advanced clear cell renal cell carcinoma.

Toni Choueiri, MD, Dana-Farber Cancer Institute

Latest:

Dr. Choueiri on the Results of the KEYNOTE-564 Study in RCC

Toni K. Choueiri, MD, discusses the results of the KEYNOTE-564 study in renal cell carcinoma.

Toni K. Choueiri, M

Latest:

Dr. Choueiri on Safety Profile of MK-6482 in Advanced Clear Cell RCC

Toni K. Choueiri, MD, discusses the safety profile of the oral HIF-2α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.